Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) will present six oncology studies at the AACR Annual Meeting, April 17-22, 2026, in San Diego. The posters use Caris' multimodal database (WES, WTS, IHC, real-world clinical data) across breast, prostate, lung and colorectal cancers.
Research highlights will be onsite at booth #1423; full abstracts follow the presentations on the company website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed, low-magnitude moves: MRNA +1.78%, MDGL +0.01%, VRNA +0.06%, while ROIV -2.89% and HALO -0.56%, suggesting this AACR-focused news is stock-specific rather than a sector-wide driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 20 | GPSai study impact | Positive | -2.1% | JAMA study showed GPSai reclassified diagnoses and changed first-line therapies. |
| Mar 16 | AI ovarian signature | Positive | +3.5% | New AI signature to predict early platinum resistance in HGSOC added to AI Insights. |
| Mar 11 | USCAP research posters | Positive | +0.4% | Five multimodal studies across sarcoma, melanoma and GIST at USCAP 2026. |
| Mar 09 | AI pancreatic signature | Positive | +2.2% | Caris AI Insights signature to guide first-line PDAC therapy and de-escalation decisions. |
| Feb 26 | Achieve 1 interim data | Positive | +4.7% | Interim Caris Detect data with early-stage sensitivity and high specificity readout. |
Recent science and AI-related announcements have mostly seen share price gains, with one notable selloff after positive GPSai data.
Over the last month, Caris released several precision oncology and AI milestones. On Feb 26, an interim Achieve 1 readout for Caris Detect reported early-stage sensitivity and high specificity. In March, the company launched new Caris AI Insights signatures in pancreatic and ovarian cancers and highlighted GPSai’s impact on correcting misdiagnoses. It also promoted multimodal studies at the USCAP meeting. Today’s AACR-focused announcement extends this pattern of showcasing its large-scale WES/WTS/IHC and real-world clinico-genomic platform across major tumor types.
Market Pulse Summary
This announcement highlights six oncology studies at AACR 2026 that leverage Caris’ multimodal WES/WTS/IHC and real-world data platform across breast, prostate, lung and colorectal cancers. It builds on recent interim results for Caris Detect and multiple Caris AI Insights signatures in pancreatic and ovarian cancer. Key factors to watch include the robustness of study datasets, clinical impact on treatment decisions, publication follow-through, and how effectively Caris converts this growing evidence base into broader clinical and biopharma adoption.
Key Terms
immunohistochemistry medical
triple-negative breast cancer medical
nsclc medical
metastatic castration resistance prostate cancer medical
microsatellite instability medical
er+/her2- medical
AI-generated analysis. Not financial advice.
These studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), immunohistochemistry (IHC) and real world clinical data, to generate clinically meaningful insights across multiple tumor types. This research reflects Caris' commitment to advancing precision oncology through deep molecular interrogation. The studies focused on breast, prostate, lung and colorectal cancers represent a collaborative effort between Caris and leading cancer centers and institutions, underscoring the power of large‑scale, real world molecular evidence to accelerate discovery and improve patient outcomes.
"These studies demonstrate the transformative potential of multimodal molecular data to uncover clinically meaningful patterns that would otherwise remain hidden," said James Hamrick, MD, MPH, Chairman of the Caris POA. "By combining deep genomic profiling with real world clinical evidence, Caris and its collaborators are generating insights that can directly inform treatment decisions and accelerate the development of more effective therapies for patients."
Posters Include:
- Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer
Session: Spatial Proteomics and Transcriptomics 1
Sunday, April 19, 2026, 2:00 PM – 5:00 PM PST
Poster #: 1200/1
Location: Poster section 47 - Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLC
Session: Biomarkers Predictive of Therapeutic Benefit 3
Monday, April 20, 2026, 9:00 AM – 12:00 PM PST
Poster #: 2434/4
Location: Poster section 40 - AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC)
Session: Molecular Targeted Therapy
Monday, April 20, 2026, 2:00 PM – 5:00 PM PST
Poster #: 3910/16
Location: Poster section 47 - cBioPortal for cancer genomics
Session: AACR Project GENIE: Genomic Characterization
Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PST
Poster #: 4097/2
Location: Poster section 1 - Distinct KRAS mutation codons differentially associate with microsatellite instability in colorectal carcinoma
Session: Precision Oncology and Real World Data
Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PST
Poster #: 5336/4
Location: Poster section 46 - MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance
Session: Real World Data to Provide Real World Evidence
Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PST
Poster #: 6647/16
Location: Poster section 47
Research highlights will be available onsite at Caris' booth #1423. The full abstracts will be available on the Caris website following the presentations.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-six-oncology-studies-utilizing-proprietary-multimodal-data-at-the-aacr-annual-meeting-2026-302724354.html
SOURCE Caris Life Sciences
FAQ
What studies will Caris (CAI) present at AACR 2026 and when are the sessions scheduled?
How does Caris (CAI) describe the data used in its AACR 2026 posters?
Where and when can attendees find Caris (CAI) research highlights at AACR 2026?
Which tumor types are covered by Caris (CAI) presentations at AACR April 2026?
Will Caris (CAI) provide full abstracts for the AACR 2026 posters online?
What is the significance of Caris (CAI) presenting at AACR 2026 for investors?
